maliqun61 schreef op 22 december 2018 07:06:
[...]
Het HAEi magazine heb ik ook even doorgenomen:
A
Pag 60/61: Ruconest en Firazyr mbt zwangerschap
Pag 68/69: Ruconest vs Firazyr mbt effectiviteit
mbt pag 60/61 Ruconest en Firazyr
Treatment of HAE Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy – by R. Hakl, St. Anne’s University Hospital, Czech Republic, et al.: The results show good C1-INH or icatibant treatment efficacy for HAE attacks in pregnancy. The treatment by the first drug used was effective in 93.7% of all attacks. In 6.3% of attacks, a second treatment had to be used. No adverse effects were observed. (J Clin Immunol., October 2018)
zie ook:
www.ncbi.nlm.nih.gov/pubmed/30280305Conclusions
Our results show good C1-INH or icatibant treatment efficacy for HAE attacks in pregnancy. The treatment by the first drug used was effective in 93.7% of all attacks. In 6.3% of attacks, a second treatment had to be used. No adverse effects were observed.
en
angioedemanews.com/2018/10/23/rucones...Ruconest (recombinant C1-inhibitor, rhC1-INH) and Firazyr (icatibant) are safe and effective approaches as first-line treatment for hereditary angioedema (HAE) attacks in pregnant women, a study suggests.
mbt Pag 68/69: ruconest vs firazyr
In the study, Ruconest® showed 100% efficacy with first dose at appropriate clinical levels. In two cases, additional therapy was applied because of initial underdosing of the first treatment. Cinryze® and Berinert® also showed good results. The main difference, however, was shown in those patients who selected Firazyr® as their first line therapy. These patients recorded re-dosing rates that were higher than controlled clinical studies have indicated before.
Of the 25 attacks treated with Firazyr® as a first line therapy, 11 (44%) failed on the first dose. In eight of those 11 failed therapy situations (72%), the patient took a second dose of Firazyr® to try to end the attack. In the other three cases, the patients took a C1 esterase inhibitor (two taking Berinert®, and one Ruconest®).
B
UK pag 56
We have also had success over the summer with the devolved governments, Scotland accepting an application for Ruconest to be available to Scottish patients, and Wales allowing Icatibant and Ruconest to be available. This means they are automatically funded by NHS Scotland/NHS Wales and are freely available for prescription.
C
Pag 43 december nummer
HAE in the United States
• Patients Estimated 6-10,000
haei.org/wp-content/uploads/2018/12/h...Pag 31 juli nummer
Country: USA
• Number of patients: Estimated 6,000-6,500
• Members of organization: 5,900
haei.org/wp-content/uploads/2018/07/h...